150.51

0.46% -0.69

After Hours: 134.50 -16.01 -10.64%

Neurocrine Biosciences Inc (NBIX)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Neurocrine Biosciences Inc stock is traded at $150.51, with a volume of 1.27M. It is down -0.46% in the last 24 hours and up +9.98% over the past month. Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Previous Close:

$151.20

Open:

$151.67

24h Volume:

1.27M

Relative Volume:

1.32

Market Cap:

$15.24B

Revenue:

$2.24B

Net Income/Loss:

$385.90M

P/E Ratio:

40.35

EPS:

3.73

Net Cash Flow:

$440.10M

1W Performance:

-1.81%

1M Performance:

+9.98%

6M Performance:

+3.35%

1Y Performance:

+5.28%

1-Day Range:

$150.00

$153.10

1-Week Range:

$148.02

$154.35

52-Week Range:

$110.95

$157.98

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name

Neurocrine Biosciences Inc

Sector

Healthcare (1177)

Industry

Drug Manufacturers - Specialty & Generic (1)

Phone

(858) 617-7600

Address

6027 EDGEWOOD BEND COURT, SAN DIEGO, CA

Employee

1,700

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

NBIX's Discussions on Twitter

Compare NBIX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NBIX Neurocrine Biosciences Inc	150.51	15.24B	2.24B	385.90M	440.10M	3.73
ZTS Zoetis Inc	174.12	78.56B	9.15B	2.43B	2.31B	5.32
TAK Takeda Pharmaceutical Co Adr	13.61	43.15B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	9.51	43.00B	14.26B	1.55B	0	0.3383
TEVA Teva Pharmaceutical Industries Ltd Adr	17.29	19.59B	16.54B	-1.64B	749.00M	-1.45

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-24	Resumed	Raymond James	Outperform
Aug-29-24	Upgrade	Piper Sandler	Neutral → Overweight
Apr-24-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Dec-13-23	Resumed	Citigroup	Neutral
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Aug-21-23	Reiterated	Mizuho	Neutral
Jul-24-23	Upgrade	SVB Securities	Market Perform → Outperform
Jul-06-23	Upgrade	BMO Capital Markets	Underperform → Market Perform
May-04-23	Upgrade	Guggenheim	Neutral → Buy
Mar-30-23	Upgrade	Canaccord Genuity	Hold → Buy
Mar-03-23	Upgrade	Evercore ISI	In-line → Outperform
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-14-22	Downgrade	Evercore ISI	Outperform → In-line
Oct-11-22	Initiated	UBS	Buy
Sep-26-22	Initiated	Wells Fargo	Equal Weight
Jun-06-22	Resumed	Jefferies	Buy
Mar-03-22	Downgrade	Piper Sandler	Overweight → Neutral
Feb-25-22	Upgrade	Goldman	Neutral → Buy
Jan-18-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-19-21	Initiated	BMO Capital Markets	Underperform
Nov-17-21	Upgrade	JP Morgan	Neutral → Overweight
Oct-14-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-23-21	Resumed	Needham	Hold
Aug-06-21	Downgrade	Canaccord Genuity	Buy → Hold
May-18-21	Resumed	Goldman	Neutral
May-06-21	Upgrade	Barclays	Equal Weight → Overweight
Feb-02-21	Initiated	Raymond James	Outperform
Sep-30-20	Initiated	The Benchmark Company	Hold
Aug-04-20	Downgrade	JP Morgan	Overweight → Neutral
Jun-29-20	Downgrade	Goldman	Buy → Neutral
Jun-09-20	Initiated	Wedbush	Outperform
Mar-06-20	Initiated	Citigroup	Buy
Feb-27-20	Initiated	Barclays	Equal Weight
Feb-24-20	Initiated	William Blair	Outperform
Feb-06-20	Initiated	Mizuho	Neutral
Feb-05-20	Reiterated	H.C. Wainwright	Buy
Dec-13-19	Downgrade	Credit Suisse	Outperform → Neutral
Aug-07-19	Initiated	RBC Capital Mkts	Outperform
Jul-16-19	Initiated	Oppenheimer	Outperform
Jun-05-19	Initiated	Guggenheim	Neutral
May-21-19	Initiated	Credit Suisse	Outperform
Apr-22-19	Upgrade	JP Morgan	Neutral → Overweight
Apr-12-19	Initiated	Evercore ISI	Outperform
Feb-06-19	Reiterated	BofA/Merrill	Buy
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Dec-13-18	Initiated	Goldman	Buy
Nov-21-18	Initiated	Canaccord Genuity	Buy

View All

Neurocrine Biosciences Inc Stock (NBIX) Latest News

12:05 PM

Neurocrine Biosciences Reports Strong Growth in 2024 - TipRanks

12:05 PM

Feb 06, 2025

Jennison Associates LLC Purchases 485,894 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Feb 06, 2025

Robeco Institutional Asset Management B.V. Sells 372,648 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Feb 06, 2025

Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug - MSN

Feb 06, 2025

Neurocrine Biosciences (NBIX) Q4 Earnings and Revenues Lag Estimates - Yahoo Finance

Feb 06, 2025

Neurocrine: Q4 Earnings Snapshot -February 06, 2025 at 04:28 pm EST - Marketscreener.com

Feb 06, 2025

Earnings Flash (NBIX) Neurocrine Biosciences, Posts Q4 Revenue $627.7M, vs. FactSet Est of $629.5M - Marketscreener.com

Feb 06, 2025

Major Win for Neurocrine: Record INGREZZA Sales Hit $615M as New Drug Gets FDA Green Light - StockTitan

Feb 06, 2025

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Swedbank AB - MarketBeat

Feb 06, 2025

Chicago Partners Investment Group LLC Acquires New Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Feb 06, 2025

Feb 05, 2025

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells $413,954.44 in Stock - MarketBeat

Feb 05, 2025

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CFO Matt Abernethy Sells 1,283 Shares - MarketBeat

Feb 05, 2025

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Sells $235,572.67 in Stock - MarketBeat

Feb 05, 2025

Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 1,740 Shares of Stock - MarketBeat

Feb 05, 2025

Neurocrine Biosciences executive sells shares worth $266,024 - MSN

Feb 05, 2025

Neurocrine Biosciences officer sells $168,849 in stock - MSN

Feb 05, 2025

Neurocrine Biosciences chief legal officer sells $191,133 in stock - MSN

Feb 05, 2025

Neurocrine Biosciences CCO sells shares worth $184,598 - MSN

Feb 05, 2025

STATE STREET CORP Reduces Stake in Neurocrine Biosciences Inc - GuruFocus.com

Feb 05, 2025

Neurocrine Biosciences chief scientific officer sells $19,273 in stock - MSN

Feb 05, 2025

Neurocrine Biosciences CCO sells shares worth $184,598 By Investing.com - Investing.com South Africa

Feb 05, 2025

Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Recent Stock Performance Tethered To Its Strong Fundamentals? - Simply Wall St

Feb 05, 2025

Neurocrine Biosciences chief medical officer sells $222,636 in stock - MSN

Feb 05, 2025

China Universal Asset Management Co. Ltd. Acquires 2,047 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Feb 05, 2025

Feb 04, 2025

Neurocrine Biosciences CEO sells $235,577 in stock By Investing.com - Investing.com Canada

Feb 04, 2025

Neurocrine Biosciences chief legal officer sells $191,133 in stock By Investing.com - Investing.com Australia

Feb 04, 2025

Neurocrine Biosciences director Kevin Gorman sells $413,966 in stock - MSN

Feb 04, 2025

Neurocrine Biosciences officer sells $168,849 in stock By Investing.com - Investing.com Canada

Feb 04, 2025

Neurocrine Biosciences executive sells shares worth $266,024 By Investing.com - Investing.com South Africa

Feb 04, 2025

Neurocrine Biosciences CFO sells shares worth $196,135 By Investing.com - Investing.com Nigeria

Feb 04, 2025

Neurocrine Biosciences chief medical officer sells $222,636 in stock By Investing.com - Investing.com UK

Feb 04, 2025

Neurocrine Biosciences CFO sells shares worth $196,135 - Investing.com

Feb 04, 2025

Neurocrine Biosciences Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) - Benzinga

Feb 04, 2025

Neurocrine Biosciences' SWOT analysis: stock outlook amid pipeline progress and market challenges - MSN

Feb 04, 2025